Clinical trial
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or…
NCT00462982 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00462982 |
|---|---|
| Title | Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma |
| Official title | A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer, Melanoma (Skin), Metastatic Cancer |
| Intervention type | Drug |
| Interventions | sunitinib malate |
| Enrollment | 8 |
| Start date | Mar 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Apr 19, 2007 |
| Last update posted | Dec 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: